Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synairgen to receive Japanese patent for inhaled IFN-beta
The patent is a part of patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. Using in vitro human models, it was discovered
The patent is a part of patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. Using in vitro human models, it was discovered
FluMist is indicated for the prevention of influenza and for the active immunization of patients from 2 years to 49 years of age against influenza disease linked with
The NDA filling is backed by complete clinical and manufacturing program of MoxDuo IR. The NDA filing will help QRxPharma to register the drug in Europe, Australia, Canada
Developed by GW Pharma, Sativex oromucosal spray is indicated as a treatment for the relief of spasticity in multiple sclerosis (MS). The spray is already been marketed in
Nizatidine is indicated for the treatment for gastric and duodenal ulcers. It blocks one of the chemicals (histamine) that stimulates the production of stomach acid. Following the approval,
The vaccine showed almost 90% difference in viral count in HIV-infected patients in comparison to placebo group, following a single vaccine injection. SEEK claims its HIV-v vaccine targets
The results of the trial demonstrated that levomilnacipran showed improvement in all dose groups, in comparison to placebo. Levomilnacipran, a sustained-release formulation, once-daily treatment was well tolerated in
The tie up aims for the development of practical synthetic routes to complex natural products of importance for the treatment of skin diseases. LEO Pharma New Product Discovery
Teva has admitted that its generic drug Neutroval infringes Amgen’s two patents. The two patents at issue in the litigation, US patent nos. 5,580,755 and 5,582,823, expire in
The company intends to send around 30 million doses of its US Food and Drug Administration (FDA) approved seasonal influenza vaccine for the US market. Novartis‘ Fluvirin influenza